Immuron launch PROIBS for Irritable Bowel Syndrome (IBS) Melbourne, Australia

Immuron launch PROIBS for Irritable

Bowel Syndrome (IBS)

Melbourne, Australia, October 24, 2025: Immuron

Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the official

launch of PROIBS into the Australian market. Immuron has already received pharmacy orders for the innovative product

that treats the symptoms of medically diagnosed Irritable Bowel Syndrome (IBS). Immuron has been a leader in digestive health in Australia

for many years. PROIBS will join Immuron's product portfolio which includes the rapidly growing Travelan brand building

on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.

Flavio Palumbo, Chief Commercial Officer said

"It has been a lot of work to develop an accelerated launch for PROIBS in Australia, right in time for the peak festive season

where IBS symptom triggers are highest. Our launch will focus on online and selected pharmacies to begin, supported by an awareness and

trial campaign across digital marketing and social media. We understand the consumer's universal truth that IBS sufferers struggle

to find solutions that work and are easy to use. PROIBS solves that, and our initial focus will be on communicating that finally

there is a relief for their IBS symptoms. We believe once Australian consumers try PROIBS , they will love it!"

Irritable bowel syndrome (IBS) is a common condition

where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress

levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS

include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.1

According to available data, the IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal

Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.2

This release has been authorised by the directors of Immuron Limited.

Immuron Limited (ASX:

IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal

antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information

visit: https://www.immuron.com.au

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,

each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development

programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations

and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock

value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth

strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the

results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties

relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key

personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and

intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in

our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.